Thierry M. Jahan, MD
The investigational cancer vaccine CRS-207 may improve response and survival when given with chemotherapy in patients with malignant pleural mesothelioma (MPM) according to results of a phase Ib trial.1
Immunohistochemistry data from 3 patients revealed an increase in tumor-infiltrating lymphocytes (TILs) post–CRS-207. Treatment-associated changes in circulating immune cells and biomarkers were also observed.
The most commonly reported treatment-related adverse events (AEs) include grade 1/2 infusion-related fever, chills/rigors, hypotension, and nausea/vomiting with no treatment-related serious AEs or deaths.
... to read the full story